Crinetics Pharmaceuticals marked a pivotal milestone in late 2025 with the FDA approval and U.S. commercial launch of PALSONIFY, the first oral somatostatin receptor ligand for acromegaly. Despite this transition to commercialization, revenue remains modest with full-cycle market adoption yet to be realized. The company's robust clinical pipeline, including later-stage candidates atumelnant and CRN09682, underpins future growth prospects, although significant regulatory and commercialization risks linger. Financially, Crinetics shows steep negative returns on equity, substantial operating losses, and negative cash flows reflecting heavy investment in development and early commercialization activities.